Allon Therapeutics Inc., of Vancouver, British Columbia, was granted a patent covering additional composition of matter for products in its ADNP platform. Claims relate to the nucleic acid composition of its neuroprotective peptide candidates AL-108 and AL-208, which are in Phase II trials.

BioMicro Systems, of Salt Lake City, was awarded U.S. Patent No. 7,223,363, or the "MAUI Hybridization System Patent," which covers the invention of a microfluidic interface with microarrays to enable researchers the ability to achieve a three- to 10-fold increase in sensitivity and consistent/reproducible results compared to traditional coverslip or static microarray hybridization methods.

Biomoda Inc., of Albuquerque, N.M., has a patent pending to enhance the stability and greatly increase the shelf life of its assay.

Caliper Life Sciences Inc., of Hopkinton, Mass., received a notice of allowance for a patent, titled "Non-invasive localization of a light-emitting conjugate in a mammal." That covers key methods of biophotonic imaging, in vivo, non-invasive in imaging of light generated from within mammals.

Chembio Diagnostic Inc., of New York, received U.S. Patent No. 7,192,721, covering a test and methodology for rapidly detecting tuberculosis in multiple animal species.

Chromatin Inc., of Chicago, was granted U.S. Patent Nos. 7,227,057 and 7,226,782, titled "Plant Centromere Compositions," and U.S. Patent No. 7,193,128, titled "Methods For Generating Or Increasing Revenues From Crops." Those patents relate to the company's gene-stacking technology for introducing several agricultural trait genes or produce biochemicals, pharmaceuticals or biofuels in crop plants.

diaDexus Inc., of South San Francisco, received U.S. Patent No. 7,217,535, which covers methods of diagnosing an individual's susceptibility for developing atherosclerotic disease, including myocardial infarction and stroke, by analyzing a blood sample for lipoprotein-associated phospholipase A2 enzymatic activity.

Generex Biotechnology Corp., of Worcester, Mass., said its wholly owned subsidiary, Antigen Express Inc., was awarded two patents relating to its core vaccine technology platform. The first patent is titled "Ii-Key/Antigenic Epitope Hybrid Peptide Vaccine," and the second is titled "Hybrid Peptides Modulate the Immune Response."

Greenovation Biotech GmbH, of Heilbronn, Germany, was granted a patent protecting its targeted processing of a plant-specific sugar residue. It's the first U.S. patent for the company's glyco-engineering work.

HistoRx Inc., of New Haven, Conn., was granted U.S. Patent No. 7,219,016, titled "Systems and Methods for Automated Analysis of Cells and Tissues," which covers the AQUA technology process, particularly the PLACE (Pixel Locale Assignment for Compartmentalization of Expression) method. That technology is designed to enable in situ biomarker analysis for pathology.

Introgen Therapeutics Inc., of Austin, Texas, was awarded U.S. Patent No. 7,235,391, titled "Formulations of Adenovirus for Gene Therapy," which covers adenovirus compositions, including its product Advexin. The patent relates to improved pharmaceutical formulations for the long-term storage of adenoviruses.

Merrimack Pharmaceuticals, of Cambridge, Mass., was issued U.S. Patent No. 7,208,576, titled "Non-glycosylated Human Alpha-fetoprotein, Methods of Production, and Uses Thereof," which covers the composition of matter for its immunomodulator MM-093.

Nastech Pharmaceuticals Co. Inc., of Bothell, Wash., received U.S. Patent No. 7,229,636, titled "Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery." That patent relates to Nascobal Nasal Spray, which Nastech manufactures for QOL Medical LLC.

Neose Technologies Inc., of Horsham, Pa., received U.S. Patent No. 7,214,660, titled "Erythropoietin: remodeling and glycoconjugation of erythropoietin," which covers the company's GlycoPEGylated erythropoietin (NE-180). The patent includes covalent conjugates of an erythropoietin peptide and a poly(ethylene)glycol and methods of forming covalent conjugates between an erythropoietin peptide and a water-soluble polymer.

NVE Corp., of Eden Prairie, Minn., was granted U.S. Patent No. 7,235,969, titled "Thin-Filmed Structure Magnetizable Bead Detector," and 7,238, 539, titled "Magnetizable Bead Detector." Both relate to the company's laboratory-on-a-chip technology.

Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,223,585, titled "Viral Purification Methods." The claims cover the production and purification of viruses, including reovirus.

Rexahn Pharmaceuticals Inc., of Rockville, Md., received U.S. Patent No. 7,205,283, titled "Antisense Oligonucleotides that Inhibit Expression of HIF-1." It covers the cancer compound RX-0047, as well as a method of inhibiting HIF-1 expression in human cells or tissues.

Rosetta Genomics Ltd., of Rehovot, Israel, received U.S. Patent No. 7,217,807, covering the composition of matter directed at a specific microRNA gene found in HIV. The company said it marked the first patent for a microRNA gene.

No Comments